Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss

Matija Snuderl, April F. Eichler, Keith L. Ligon, Quynh U. Vu, Michael Silver, Rebecca Betensky, Azra H. Ligon, Patrick Y. Wen, David N. Louis, A. John Iafrate

Research output: Contribution to journalArticle

Abstract

Purpose: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis. The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion. Experimental Design: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done. Polysomy was defined as more than two 1q and 19p signals in >30% of the cells with concurrent 1p/19q deletion. Tumors were divided into groups based on their 1p/19q status and compared for progression-free survival, overall survival, and 5-year survival probabilities. Results: Forty-six tumors (72%) in our cohort had 1p/19q loss and 18 (28%) had 1p/19q maintenance. Of those with loss, 19 (41%) had concurrent polysomy and 27 (59%) lacked polysomy. In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and over-all survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively). Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048). Overall survival was similar in tumors with and without polysomy. The Ki-67 labeling index was not associated with polysomy and did not have prognostic significance. Conclusion: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.

Original languageEnglish (US)
Pages (from-to)6430-6437
Number of pages8
JournalClinical Cancer Research
Volume15
Issue number20
DOIs
StatePublished - Oct 15 2009

Fingerprint

Chromosomes, Human, Pair 19
Oligodendroglioma
Chromosomes, Human, Pair 1
Recurrence
Disease-Free Survival
Survival
Maintenance
Neoplasms
Fluorescence In Situ Hybridization
General Hospitals
Research Design
Chromosomes
Immunohistochemistry
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. / Snuderl, Matija; Eichler, April F.; Ligon, Keith L.; Vu, Quynh U.; Silver, Michael; Betensky, Rebecca; Ligon, Azra H.; Wen, Patrick Y.; Louis, David N.; Iafrate, A. John.

In: Clinical Cancer Research, Vol. 15, No. 20, 15.10.2009, p. 6430-6437.

Research output: Contribution to journalArticle

Snuderl, M, Eichler, AF, Ligon, KL, Vu, QU, Silver, M, Betensky, R, Ligon, AH, Wen, PY, Louis, DN & Iafrate, AJ 2009, 'Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss', Clinical Cancer Research, vol. 15, no. 20, pp. 6430-6437. https://doi.org/10.1158/1078-0432.CCR-09-0867
Snuderl, Matija ; Eichler, April F. ; Ligon, Keith L. ; Vu, Quynh U. ; Silver, Michael ; Betensky, Rebecca ; Ligon, Azra H. ; Wen, Patrick Y. ; Louis, David N. ; Iafrate, A. John. / Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 20. pp. 6430-6437.
@article{2121a659dd0d40968b9a74c0b05923fa,
title = "Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss",
abstract = "Purpose: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis. The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion. Experimental Design: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done. Polysomy was defined as more than two 1q and 19p signals in >30{\%} of the cells with concurrent 1p/19q deletion. Tumors were divided into groups based on their 1p/19q status and compared for progression-free survival, overall survival, and 5-year survival probabilities. Results: Forty-six tumors (72{\%}) in our cohort had 1p/19q loss and 18 (28{\%}) had 1p/19q maintenance. Of those with loss, 19 (41{\%}) had concurrent polysomy and 27 (59{\%}) lacked polysomy. In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and over-all survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively). Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048). Overall survival was similar in tumors with and without polysomy. The Ki-67 labeling index was not associated with polysomy and did not have prognostic significance. Conclusion: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.",
author = "Matija Snuderl and Eichler, {April F.} and Ligon, {Keith L.} and Vu, {Quynh U.} and Michael Silver and Rebecca Betensky and Ligon, {Azra H.} and Wen, {Patrick Y.} and Louis, {David N.} and Iafrate, {A. John}",
year = "2009",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-09-0867",
language = "English (US)",
volume = "15",
pages = "6430--6437",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss

AU - Snuderl, Matija

AU - Eichler, April F.

AU - Ligon, Keith L.

AU - Vu, Quynh U.

AU - Silver, Michael

AU - Betensky, Rebecca

AU - Ligon, Azra H.

AU - Wen, Patrick Y.

AU - Louis, David N.

AU - Iafrate, A. John

PY - 2009/10/15

Y1 - 2009/10/15

N2 - Purpose: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis. The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion. Experimental Design: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done. Polysomy was defined as more than two 1q and 19p signals in >30% of the cells with concurrent 1p/19q deletion. Tumors were divided into groups based on their 1p/19q status and compared for progression-free survival, overall survival, and 5-year survival probabilities. Results: Forty-six tumors (72%) in our cohort had 1p/19q loss and 18 (28%) had 1p/19q maintenance. Of those with loss, 19 (41%) had concurrent polysomy and 27 (59%) lacked polysomy. In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and over-all survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively). Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048). Overall survival was similar in tumors with and without polysomy. The Ki-67 labeling index was not associated with polysomy and did not have prognostic significance. Conclusion: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.

AB - Purpose: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis. The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion. Experimental Design: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done. Polysomy was defined as more than two 1q and 19p signals in >30% of the cells with concurrent 1p/19q deletion. Tumors were divided into groups based on their 1p/19q status and compared for progression-free survival, overall survival, and 5-year survival probabilities. Results: Forty-six tumors (72%) in our cohort had 1p/19q loss and 18 (28%) had 1p/19q maintenance. Of those with loss, 19 (41%) had concurrent polysomy and 27 (59%) lacked polysomy. In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and over-all survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively). Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048). Overall survival was similar in tumors with and without polysomy. The Ki-67 labeling index was not associated with polysomy and did not have prognostic significance. Conclusion: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.

UR - http://www.scopus.com/inward/record.url?scp=70350223970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350223970&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-0867

DO - 10.1158/1078-0432.CCR-09-0867

M3 - Article

C2 - 19808867

AN - SCOPUS:70350223970

VL - 15

SP - 6430

EP - 6437

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -